Filing Flows › Mimedx Group (MDXG) › R&D spending
Mimedx Group (MDXG) R&D spending by quarter
Mimedx Group's R&D spending was $2.8M in Q3 2026 (third quarter 2026), +0.7% from Q2 2026. Over the last 7 quarters it ranged from $2.8M (Q2 2026) to $4.8M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.8M | +0.7% | -24% |
| Q2 2026 | $2.8M | -33% | -16% |
| Q1 2026 | $4.1M | -13% | +24% |
| Q4 2025 | $4.8M | +29% | — |
| Q3 2025 | $3.7M | +12% | — |
| Q2 2025 | $3.3M | -0.8% | — |
| Q1 2025 | $3.3M | — | — |
Q3 2026 at a glance
Mimedx Group, Q3 2026: revenue $62.3M (-45% year over year), operating margin -18.8%, net loss $8.7M, operating cash flow $3.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Mimedx Group's R&D spending?
Mimedx Group's R&D spending was $2.8M in Q3 2026 (third quarter 2026), +0.7% from Q2 2026.
How has Mimedx Group's R&D spending changed?
Over the last 7 quarters it ranged from $2.8M (Q2 2026) to $4.8M (Q4 2025).